Home/Pipeline/PB004 / PBA-0405

PB004 / PBA-0405

Cancer

Phase 0Active

Key Facts

Indication

Cancer

Phase

Phase 0

Status

Active

Company

Pure Biologics

About Pure Biologics

Pure Biologics is a publicly traded biotech company based in Poland, specializing in the development of novel antibody and aptamer-based therapeutics for immuno-oncology. It has built a proprietary technology platform for selecting active molecules and has progressed two lead candidates, PB004 and PB003G, into Phase 0 clinical studies with FDA approvals. The company's strategy is to achieve financial independence by commercializing its therapeutic candidates to fund further advanced R&D projects.

View full company profile

Therapeutic Areas

Oncology Immuno-oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active